4D Molecular Therapeutics, Inc.

NASDAQ:FDMT

Biotechnology

Healthcare
$10.79 +1.70%

+$0.16 today

Market cap
$596.08M
Beta
2.76
P/E (TTM)
-4.0
EPS (TTM)
-$2.36
52W Low $3.68High $12.34

Volume 0.81M

Average 0.77M

Returns on capital

4D Molecular Therapeutics, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-27.7%

avg -2.6%

ROIC

-30.2%

avg -40.2%

ROA

-24.7%

avg -33.3%

Analysis

ROA is currently the strongest return metric at -24.7% versus its period average of -33.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

David H. Kirn

Co-Founder, President, CEO & DirectorUSD 1.23M64——

Fariborz Kamal

Chief Technical AdvisorUSD 892.87K63178.40K0.34%

Theresa Janke

Co-Founder & Chief of StaffUSD 652.32K51——

Noriyuki Kasahara

Chief Scientific AdvisorUSD 201.29K6322.50K0.04%

John F. Milligan

Executive ChairmanUSD 150K6575.00K0.14%

Kristian Humer

CFO and Principal Financial & Accounting OfficerUSD 116.25K500<0.01%

An Song

Chief Translational Medicine Advisor————

Scott Bizily

Chief Legal Officer & Corporate Secretary—548.62K0.02%

Julian Pei

Head of Investor Relations & Corporate Finance————

Katy Barglow

Chief Technical Officer————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Oct 16, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

0

$0.00

Sells

24

$5.34M

Net Transaction Value

−$5.34M

Net selling

Most Active

Kirn David

12 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Oct 16, 26

Bizily Scott

Direct

Sell$21K
Oct 5, 26

Kirn David

Direct

Sell$750.2K
Oct 5, 26

Kirn David

Direct

Sell$3.7K
Sep 16, 26

Bizily Scott

Direct

Sell$22.3K
Sep 14, 26

Kirn David

Direct

Sell$811K
Sep 1, 26

Bizily Scott

Direct

Sell$8.2K
Aug 19, 26

Kirn David

Direct

Sell$662.6K
Aug 19, 26

Kirn David

Direct

Sell$425.7K
Aug 17, 26

Bizily Scott

Direct

Sell$19.9K
Aug 13, 26

Bizily Scott

Direct

Sell$19.6K

1–10 of 24

Summary

Insiders reported 0 buys worth $0.00 and 24 sells worth $5.34M over the last 12 months. That adds up to net selling of $5.34M. Kirn David was the most active insider with 12 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/A+200.9%
+37.5% (5yr)3 analysts
Net IncomeN/AN/AN/A
N/A3 analysts
EBITN/AN/AN/A
N/A3 analysts

Analysis

Recent growth has been strongest in Revenue at +200.9% over three years. Forward estimates point to Revenue at +37.5% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does 4D Molecular Therapeutics, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about FDMT's management, answered from reported figures.

Who manages FDMT?

4D Molecular Therapeutics, Inc. (FDMT) lists 10 active executives. The top listed executive is John F. Milligan, Executive Chairman.

Are FDMT insiders buying or selling?

Recent insider activity shows net buying of $18.32M.